Alyeska Investment Group, L.P. In8 Bio, Inc. Transaction History
Alyeska Investment Group, L.P.
- $16.5 Billion
- Q2 2024
A detailed history of Alyeska Investment Group, L.P. transactions in In8 Bio, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 641,008 shares of INAB stock, worth $192,302. This represents 0.0% of its overall portfolio holdings.
Number of Shares
641,008
Previous 446,016
43.72%
Holding current value
$192,302
Previous $526,000
3.42%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding INAB
# of Institutions
27Shares Held
7.74MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD2.13MShares$638,3990.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$427,1690.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.12MShares$335,4790.0% of portfolio
-
Sigma Planning Corp Ann Arbor, MI600KShares$179,9040.02% of portfolio
-
683 Capital Management, LLC New York, NY591KShares$177,2430.05% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $7.35M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...